Questions? Feedback? powered by Olark live chat software
All Site

We are very pleased to announce that Terumo BCT has appointed In Vitro Technologies as their new distributor in Australia and New Zealand effective 1 June 2018, supporting the Cell Therapy Technologies range of products.

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. Terumo BCT believes in the potential of blood to do even more for patients than it does today. This belief inspires its innovation and strengthens its collaboration with customers. Terumo BCT’s Cell Therapy Technologies portfolio includes:

  • Quantum® Cell Expansion System: Automated, functionally closed cell expansion system for the reproducible large-scale culture of adherent and suspension cells.
  • Elutra® Cell Separation System: Cell separation system for the convenient separation of cell populations into high-purity, high-yield cell products.
  • COBE® 2991 Cell Processor: Cell processing system for washing and concentration of cells intended for a range of therapeutic purposes.
  • TSCD®-Q Sterile Tubing Welder for the Quantum System: Sterile tubing welder enabling strong, sterile polyurethane tubing connections.
  • SCD® IIB Sterile Tubing Welder: Sterile tubing welder capable of creating connections on polyvinyl chloride (PVC) and C-FLEX® tubing in a few simple steps.

Terumo BCT will continue to directly sell its Blood Centre, Therapeutic Apheresis and Cell Collection products.

Providing technologies that enable researchers and developers to create next-generation cell and gene therapies, Terumo BCT supports manufacturing of cell-based therapies at every phase of development with flexible solutions to meet evolving needs for reproducibility, quality and scale. Supporting research and manufacturing of cell-based therapies from benchtop research to current good manufacturing practice (cGMP) commercial manufacturing, Terumo BCT’s Quantum® Cell Expansion System allows cell culture processes to be optimized and configured to match the needs of particular cell type. Quantum maintains a consistent and controlled environment, automating critical processes such as feeding cells, removing waste and exchanging gases until it is time to harvest cells.

At In Vitro Technologies, we pride ourselves on ensuring the accuracy and reproducibility of your scientific results. The addition of Terumo BCT products strengthens our existing portfolio of translational research and clinical cell therapy brands, which includes Agilent, ACEA Biosciences, GE HyClone and R&D Systems. Providing a complete workflow for research and translation of cellular therapies, we are now, more than ever in a position to accelerate discovery into the next generation cell and immunotherapies.

Together, both Terumo BCT and In Vitro Technologies look forward to providing our customers with high efficiency, cGMP cell culture solutions that ensure high quality, reproducible therapeutic results. 

For all technical enquiries or for further information on cell therapy solutions from In Vitro Technologies, please contact our national product manager, Dr Alex Rowland on +61 423 820 705, our customer care team on 0800 468 487 or via email infonz@invitro.co.nz

02.08.2018